Healthcare of Ontario Pension Plan Trust Fund Acquires Shares of 35,950 Hims & Hers Health, Inc. $HIMS

Healthcare of Ontario Pension Plan Trust Fund bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) during the 1st quarter, Holdings Channel.com reports. The fund bought 35,950 shares of the company’s stock, valued at approximately $746,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Binnacle Investments Inc bought a new stake in Hims & Hers Health in the 3rd quarter valued at $28,000. Silicon Valley Capital Partners purchased a new position in shares of Hims & Hers Health during the third quarter valued at about $48,000. Flagship Harbor Advisors LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter worth about $28,000. Bogart Wealth LLC increased its holdings in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after buying an additional 687 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $27.79 on Monday. The firm has a market capitalization of $6.43 billion, a price-to-earnings ratio of -308.74, a PEG ratio of 78.15 and a beta of 2.40. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43. The business has a 50 day simple moving average of $31.23 and a 200-day simple moving average of $26.08. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same period in the prior year, the firm posted $0.20 EPS. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on HIMS shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 price target on shares of Hims & Hers Health in a report on Tuesday, May 5th. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Needham & Company LLC raised their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. reduced their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Finally, UBS Group set a $23.00 price target on shares of Hims & Hers Health in a research note on Friday, May 22nd. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $31.43.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the transaction, the chief operating officer owned 432,124 shares in the company, valued at $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the sale, the insider directly owned 181,861 shares in the company, valued at approximately $6,365,135. This represents a 11.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,126 shares of company stock valued at $2,711,339 over the last three months. Corporate insiders own 11.76% of the company’s stock.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: One bullish analysis argues that Hims & Hers remains undervalued, citing projected revenue growth, approximately 73% gross margins, accelerating subscriber additions, GLP-1 and peptide demand, international expansion, and the Novo Nordisk partnership. The thesis suggests substantial long-term upside if the company sustains growth despite the regulatory controversy. Hims & Hers Health: Still an Undervalued Company With Tremendous Upside
• Neutral Sentiment: Several law firms, including SBS Law, Kaplan Fox, Howard G. Smith, and Holzer & Holzer, announced investigations into possible securities-law violations. These announcements are typically investor-solicitation notices and do not establish wrongdoing, but they raise the possibility of shareholder litigation and additional disclosure obligations. SBS Law Investigation
• Negative Sentiment: The FTC alleges Hims & Hers shared customers’ health information with advertising platforms including Meta and Snap, failed to clearly disclose prescription charges, and used potentially deceptive billing and privacy practices. The lawsuit could lead to penalties, higher compliance expenses, tighter restrictions on marketing, and damage to consumer trust. Media coverage of the action contributed to a sharp decline in the shares and remains the principal near-term risk for HIMS. FTC Sues Hims & Hers

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.